Nautilus Biotechnology (NAUT) Depreciation & Amortization (CF) (2020 - 2026)

Nautilus Biotechnology has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $334000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $334000.0, down 28.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 21.93% YoY), and the FY2025 annual result was $1.7 million, down 15.0% from the prior year.
• Depreciation & Amortization (CF) came in at $334000.0 for Q1 2026 at Nautilus Biotechnology, down from $400000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $549000.0 in Q4 2023 to a low of $300000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $400000.0 (2023), against an average of $413705.9.
• Across the five-year window, Depreciation & Amortization (CF) surged 83.0% in 2023 and dropped 28.17% in 2026, its largest moves.
• Nautilus Biotechnology's Depreciation & Amortization (CF) stood at $300000.0 in 2022, then soared by 83.0% to $549000.0 in 2023, then dropped by 8.93% to $500000.0 in 2024, then retreated by 20.0% to $400000.0 in 2025, then slipped by 16.5% to $334000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $334000.0 (Q1 2026), $400000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.